[
  {
    "ts": null,
    "headline": "Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Patients treated with tirzepatide also experienced notable improvements in heart failure symptoms and physical limitations. The results were published in The New England Journal of Medicine simultaneously with a presentation at the Ame",
    "url": "https://finnhub.io/api/news?id=5ab8b9c5191866e691d266152180d46dd0e77cb30ef7fb4451cae7d7e3ab5858",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731769200,
      "headline": "Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity",
      "id": 131396934,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Patients treated with tirzepatide also experienced notable improvements in heart failure symptoms and physical limitations. The results were published in The New England Journal of Medicine simultaneously with a presentation at the Ame",
      "url": "https://finnhub.io/api/news?id=5ab8b9c5191866e691d266152180d46dd0e77cb30ef7fb4451cae7d7e3ab5858"
    }
  },
  {
    "ts": null,
    "headline": "The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?",
    "summary": "The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.",
    "url": "https://finnhub.io/api/news?id=123d0bbd8fcfa38ae969f58b412123706f312a0a34444ac3d2cd0d7dd24e8ace",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731765632,
      "headline": "The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?",
      "id": 131393742,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.",
      "url": "https://finnhub.io/api/news?id=123d0bbd8fcfa38ae969f58b412123706f312a0a34444ac3d2cd0d7dd24e8ace"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
    "summary": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
    "url": "https://finnhub.io/api/news?id=ab35bbf6e6167949d1e4b443451c38935553ca9594b036143aefdeef7f7206ad",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731741420,
      "headline": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
      "id": 131413506,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
      "url": "https://finnhub.io/api/news?id=ab35bbf6e6167949d1e4b443451c38935553ca9594b036143aefdeef7f7206ad"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
    "summary": "Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=ae67a1da1b3da778c24ac56d0dd030b8f3742f591a9569de4bb0f87f530c1136",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731730369,
      "headline": "Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
      "id": 131387060,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ae67a1da1b3da778c24ac56d0dd030b8f3742f591a9569de4bb0f87f530c1136"
    }
  }
]